<SEC-DOCUMENT>0001178913-25-002880.txt : 20250814
<SEC-HEADER>0001178913-25-002880.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814070021
ACCESSION NUMBER:		0001178913-25-002880
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250814
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		251214229

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2533655.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 25.5.1.5318
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: Arial; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';"><font style="font-size: 14pt; font-weight: bold;">UNITED STATES&#160;</font><font style="font-size: 14pt;">&#160;&#160;</font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">Washington, D.C.&#160;20549</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';">&#160;&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">Report of Foreign Private Issuer</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">of&#160;the Securities Exchange Act of 1934</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';">For the month of August 2025<br>
      Commission File No.:001-35773</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-size: 16pt; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';">(Translation of registrant&#8217;s name into English)</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">21 Ha&#8217;arba&#8217;a Street, Tel Aviv, 6473921, Israel</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';">(Address of principal executive offices)</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman';">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman';">Form 20-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160; &#160; &#160;&#160; &#160; Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2,
      2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No.
      333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327) and on March 25, 2025 (File No.
      333-286082), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on
      August 9, 2024 (File No. 333-281417).</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">On August 8, 2025, the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;<u>Nasdaq</u>&#8221;) issued an extension letter granting RedHill Biopharma Ltd.
      (the &#8220;<u>Company</u>&#8221;) additional time until October 13, 2025 to regain compliance with Nasdaq Listing Rule 5550(b), which requires listed companies to maintain a minimum stockholders&#8217; equity of $2,500,000 for continued listing (the &#8220;<u>Rule</u>&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">As previously reported, on April 15, 2025 the Company received a written notification of a deficiency letter from Nasdaq notifying the Company that it no longer
      complies with the Rule. The Company submitted a plan to Nasdaq to regain compliance, and Nasdaq responded with the extension letter referred to above.</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">
      <div style="line-height: 1.25;">In the event the Company does not regain compliance by October 13, 2025, the Company may appeal Staff&#8217;s determination to a Hearings Panel, which if
        accepted will provide the Company additional time to regain compliance.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;"><u>Special Note Concerning&#160;Forward&#160;Looking&#160;Statements</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-right: 0.1pt; line-height: 1.25; font-family: 'Times New Roman';">This Form 6-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities
      laws. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;will,&#8221; and similar expressions are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when
      discussing its plans to achieve compliance with Nasdaq&#8217;s stockholders&#8217; equity requirement. Because such statements deal with future events and are based on RedHill&#8217;s current expectations, they are subject to various risks and uncertainties, and
      actual results, performance, or achievements of RedHill could differ materially from those described in or implied by the statements in this Form 6-K.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">The forward-looking statements contained or implied in this Form 6-K are subject to other risks and uncertainties, including market conditions and the satisfaction of
      all conditions to, and the closing of, the financing arrangements described above, as well as those discussed in RedHill&#8217;s Annual Report on Form 20-F for the year ended December 31, 2024, and in subsequent filings with the Securities and Exchange
      Commission. Except as otherwise required by law, RedHill undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of
      unanticipated events.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">SIGNATURES</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman';">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8b02be3a9927439c96955027e44a9311">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">REDHILL BIOPHARMA LTD.</div>
          </td>
          <td style="width: 16%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">(the &#8220;<u>Registrant</u>&#8221;)</div>
          </td>
          <td style="width: 16%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 30.04%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 16%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">Date: August 14, 2025</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">By:</div>
          </td>
          <td nowrap="nowrap" style="width: 30.04%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">/s/ Dror Ben-Asher</div>
          </td>
          <td style="width: 16%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">Name:&#160;&#160;&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 30.04%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">Dror Ben-Asher</div>
          </td>
          <td style="width: 16%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 30.04%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">Chief Executive Officer</div>
          </td>
          <td style="width: 16%; vertical-align: middle;">
            <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
